Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2B | Q13224 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.44 |
| ▸ | CCR6 | P51684 | 2/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.42 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | KIF11 | P52732 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | LTA4H | P09960 | 1/20 | 0.42 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.40 |
| ▸ | SERPINE1 | P05121 | 1/20 | 0.40 |
| ▸ | SLC7A5 | Q01650 | 2/20 | 0.39 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27862141 | 0.90 | KIF11 (0.47) | GRIN2BMAPTEPHX2CCR6KCNH2 | |
| SCHEMBL168125 | 0.90 | KIF11 (0.47) | GRIN2BMAPTEPHX2CCR6KCNH2 | |
| SCHEMBL8113103 | 0.88 | GRIN2B (0.42) | GRIN2BMAPTEPHX2CCR6KCNH2 | |
| Methyl Alcohol SCHEMBL27964960 | 0.88 | CCR6 (0.47) | GRIN2BMAPTEPHX2CCR6KCNH2 | |
| SCHEMBL29087324 | 0.87 | KIF11 (0.46) | GRIN2BMAPTEPHX2CCR6KCNH2 | |
| Ammonia Solution, Strong SCHEMBL2163079 | 0.87 | KIF11 (0.46) | GRIN2BMAPTEPHX2CCR6KCNH2 | |
| Fluoride SCHEMBL28371495 | 0.87 | KIF11 (0.46) | GRIN2BMAPTEPHX2CCR6KCNH2 | |
| Hydrogen Sulfide SCHEMBL27539287 | 0.87 | KIF11 (0.46) | GRIN2BMAPTEPHX2CCR6KCNH2 | |
| SCHEMBL4036809 | 0.87 | KIF11 (0.46) | GRIN2BMAPTEPHX2CCR6KCNH2 | |
| Water SCHEMBL27610464 | 0.87 | KIF11 (0.46) | GRIN2BMAPTEPHX2CCR6KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 145 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11964944-B2 | Compounds and methods for treating, detecting, and identifying compounds to treat apicomplexan parasitic diseases | THE UNIVERSITY OF CHICAGO (US) | 2024-04-23 | — | — | US | disclosed |
| US-20230140413-A1 | Compounds and Methods for Treating, Detecting, and Identifying Compounds to Treat Apicomplexan Parasitic Diseases | THE UNIVERSITY OF CHICAGO | 2023-05-04 | — | — | US | disclosed |
| EP-3708566-B1 | NOVEL HETEROCYCLIC COMPOUNDS AND THE USE THEREOF IN MEDICINE AND IN COSMETICS | GALDERMA RES & DEV (FR) | 2023-02-08 | — | — | EP | disclosed |
| US-20220305011-A1 | FACTOR XIIA INHIBITORS | UNIVERSITY OF LEEDS (GB) | 2022-09-29 | — | — | US | disclosed |
| US-11414385-B2 | Compounds and methods for treating, detecting, and identifying compounds to treat apicomplexan parasitic diseases | THE UNIVERSITY OF CHICAGO | 2022-08-16 | — | — | US | disclosed |
| US-20200283391-A1 | Compounds and Methods for Treating, Detecting, and Identifying Compounds to Treat Apicomplexan Parasitic Diseases | THE UNIVERSITY OF CHICAGO | 2020-09-10 | — | — | US | disclosed |
| US-10246422-B2 | Heterocyclic compounds and use thereof in medicine and in cosmetics | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2019-04-02 | — | — | US | disclosed |
| EP-3394032-A1 | COMPOUNDS AND METHODS FOR TREATING, DETECTING, AND IDENTIFYING COMPOUNDS TO TREAT APICOMPLEXAN PARASITIC DISEASES | The University of Chicago (US) | 2018-10-31 | — | — | EP | disclosed |
| US-20180050992-A1 | NOVEL HETEROCYCLIC COMPOUNDS AND USE THEREOF IN MEDICINE AND IN COSMETICS | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2018-02-22 | — | — | US | disclosed |
| WO-2017112678-A1 | COMPOUNDS AND METHODS FOR TREATING, DETECTING, AND IDENTIFYING COMPOUNDS TO TREAT APICOMPLEXAN PARASITIC DISEASES | MCLEOD RIMA (US) | 2017-06-29 | — | — | WO | disclosed |
| EP-1224175-A2 | BENZODIAZEPINE DERIVATIVES AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2002-07-24 | — | — | EP | disclosed |
| US-6291511-B1 | Biarylalkanoic acids as cell adhesion inhibitors | MERCK & CO., INC. | 2001-09-18 | — | — | US | disclosed |
| WO-2001036423-A1 | SPIRO(2H-1-BENZOPYRAN-2,4'-PIPERIDINE) DERIVATES AS GLYCINE TRANSPORT INHIBITORS | AKZO NOBEL N.V. (NL) | 2001-05-25 | — | — | WO | disclosed |
| WO-2001029012-A2 | BENZODIAZEPINE DERIVATIVES AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2001-04-26 | — | — | WO | disclosed |
| EP-1017382-A4 | BIARYLALKANOIC ACIDS AS CELL ADHESION INHIBITORS | MERCK & CO INC (US) | 2000-08-30 | — | — | EP | disclosed |
| EP-1019410-A1 | SPIRO-PIPERIDINE DERIVATIVES AND THEIR USE AS TACHYKININ ANTAGONISTS | MERCK SHARP & DOHME LTD. (GB) | 2000-07-19 | — | — | EP | disclosed |
| EP-1017382-A1 | BIARYLALKANOIC ACIDS AS CELL ADHESION INHIBITORS | Merck & Co., Inc. (a New Jersey corp.) (US) | 2000-07-12 | — | — | EP | disclosed |
| US-6060469-A | Spiro-piperidine derivatives and their use as tachykinin antagonists | MERCK SHARP & DOHME LTD. (GB) | 2000-05-09 | — | — | US | disclosed |
| WO-1998053817-A1 | BIARYLALKANOIC ACIDS AS CELL ADHESION INHIBITORS | MERCK & CO., INC. (US) | 1998-12-03 | — | — | WO | disclosed |
| WO-1997019084-A1 | SPIRO-PIPERIDINE DERIVATIVES AND THEIR USE AS TACHYKININ ANTAGONISTS | MERCK SHARP & DOHME LIMITED (GB) | 1997-05-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200283391-A1 | Compounds and Methods for Treating, Detecting, and Identifying Compounds to Treat Apicomplexan Parasitic Diseases | TUBB1, MYADM, TUBB | GRIN2B 4140/4885MAPT 2969/4885EPHX2 531/4885 |
| US-11964944-B2 | Compounds and methods for treating, detecting, and identifying compounds to treat apicomplexan parasitic diseases | TUBB1, MYADM, TUBB | GRIN2B 4201/4885MAPT 2933/4885EPHX2 423/4885 |
| US-20230140413-A1 | Compounds and Methods for Treating, Detecting, and Identifying Compounds to Treat Apicomplexan Parasitic Diseases | TUBB1, MYADM, TUBB | GRIN2B 4201/4885MAPT 2933/4885EPHX2 423/4885 |
| US-11414385-B2 | Compounds and methods for treating, detecting, and identifying compounds to treat apicomplexan parasitic diseases | TUBB1, MYADM, TUBB | GRIN2B 4140/4885MAPT 2969/4885EPHX2 531/4885 |
| US-20180050992-A1 | NOVEL HETEROCYCLIC COMPOUNDS AND USE THEREOF IN MEDICINE AND IN COSMETICS | MC1R, CALCRL, BDKRB2 | GRIN2B 516/4885MAPT 3627/4885EPHX2 599/4885 |
| US-20220305011-A1 | FACTOR XIIA INHIBITORS | F11, F13B, F12 | GRIN2B 3931/4885MAPT 4436/4885EPHX2 199/4885 |
| US-10246422-B2 | Heterocyclic compounds and use thereof in medicine and in cosmetics | MC1R, BDKRB2, CCKBR | GRIN2B 551/4885MAPT 3477/4885EPHX2 609/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.